Statistics from Altmetric.com
Since the successful introduction of antivascular endothelial growth factor (VEGF) intravitreal injections (IVT) for the management of age-related macular degeneration (AMD), this treatment has gained popularity. Several studies have reported on the complications of anti-VEGF IVT, including a transient rise in intraocular pressure (IOP).1
We aimed to determine whether IOP measurement post-IVT is necessary following injection of the commonly used anti-VEGF agents: ranibizumab (Lucentis), bevacizumab (Avastin) and pegabtanib (Macugen).
This was a retrospective observational study of postinjection change in IOP in patients with neovascular AMD who received an injection of an anti-VEGF drug between September 2006 and March 2008. Patients were treated with one of three anti-VEGF drugs (ranibizumab 0.5 mg, bevacizumab 1.25 mg, pegabtanib 0.3 mg) using a sterile technique. Povidine iodine 5% preparation and topical oxybuprocaine anaesthetic …
Competing interests: None.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.